Ovid Therapeutics Inc.

NASDAQ:OVID

1.19 (USD) • At close October 29, 2024
Bedrijfsnaam Ovid Therapeutics Inc.
Symbool OVID
Munteenheid USD
Prijs 1.19
Beurswaarde 84,456,204
Dividendpercentage 0%
52-weken bereik 0.68 - 4.1
Industrie Biotechnology
Sector Healthcare
CEO Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir
Website https://www.ovidrx.com

An error occurred while fetching data.

Over Ovid Therapeutics Inc.

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment

Vergelijkbare Aandelen

Citius Pharmaceuticals, Inc. logo

Citius Pharmaceuticals, Inc.

CTXR

0.39 USD

DarioHealth Corp. logo

DarioHealth Corp.

DRIO

0.95 USD

Assertio Holdings, Inc. logo

Assertio Holdings, Inc.

ASRT

1.1 USD

IO Biotech, Inc. logo

IO Biotech, Inc.

IOBT

1.295 USD

Ikena Oncology, Inc. logo

Ikena Oncology, Inc.

IKNA

1.71 USD

Cue Biopharma, Inc. logo

Cue Biopharma, Inc.

CUE

1.69 USD

AVITA Medical, Inc. logo

AVITA Medical, Inc.

RCEL

9.96 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)